Annual EBITDA
-$297.66 M
-$15.42 M-5.46%
31 December 2023
Summary:
Pacific Biosciences of California annual earnings before interest, taxes, depreciation & amortization is currently -$297.66 million, with the most recent change of -$15.42 million (-5.46%) on 31 December 2023. During the last 3 years, it has fallen by -$336.63 million (-863.74%). PACB annual EBITDA is now -863.74% below its all-time high of $38.97 million, reached on 31 December 2020.PACB EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$53.54 M
+$101.95 M+65.57%
30 September 2024
Summary:
Pacific Biosciences of California quarterly earnings before interest, taxes, depreciation & amortization is currently -$53.54 million, with the most recent change of +$101.95 million (+65.57%) on 30 September 2024. Over the past year, it has increased by +$14.99 million (+21.88%). PACB quarterly EBITDA is now -169.27% below its all-time high of $77.28 million, reached on 31 December 2020.PACB Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$339.08 M
+$14.99 M+4.23%
30 September 2024
Summary:
Pacific Biosciences of California TTM earnings before interest, taxes, depreciation & amortization is currently -$339.08 million, with the most recent change of +$14.99 million (+4.23%) on 30 September 2024. Over the past year, it has dropped by -$53.07 million (-18.56%). PACB TTM EBITDA is now -970.02% below its all-time high of $38.97 million, reached on 31 December 2020.PACB TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PACB EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -5.5% | +21.9% | -18.6% |
| 3 y3 years | -863.7% | +25.7% | -199.8% |
| 5 y5 years | -220.3% | -106.7% | -229.0% |
PACB EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -863.7% | at low | at high | +65.6% | -199.8% | +4.2% |
| 5 y | 5 years | -863.7% | at low | -169.3% | +65.6% | -970.0% | +4.2% |
| alltime | all time | -863.7% | at low | -169.3% | +65.6% | -970.0% | +4.2% |
Pacific Biosciences Of California EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$53.54 M(-65.6%) | -$339.08 M(-4.2%) |
| June 2024 | - | -$155.49 M(+148.4%) | -$354.07 M(+36.2%) |
| Mar 2024 | - | -$62.59 M(-7.2%) | -$260.00 M(-6.2%) |
| Dec 2023 | -$297.66 M(+5.5%) | -$67.47 M(-1.6%) | -$277.28 M(-3.1%) |
| Sept 2023 | - | -$68.53 M(+11.6%) | -$286.01 M(-0.2%) |
| June 2023 | - | -$61.41 M(-23.1%) | -$286.47 M(-0.8%) |
| Mar 2023 | - | -$79.87 M(+4.8%) | -$288.65 M(+2.2%) |
| Dec 2022 | -$282.24 M(+12.6%) | -$76.19 M(+10.4%) | -$282.55 M(+6.0%) |
| Sept 2022 | - | -$68.99 M(+8.5%) | -$266.57 M(-1.1%) |
| June 2022 | - | -$63.60 M(-13.8%) | -$269.62 M(+11.9%) |
| Mar 2022 | - | -$73.76 M(+22.5%) | -$241.04 M(-3.8%) |
| Dec 2021 | -$250.76 M(-743.4%) | -$60.21 M(-16.4%) | -$250.60 M(+121.6%) |
| Sept 2021 | - | -$72.05 M(+105.7%) | -$113.11 M(+81.1%) |
| June 2021 | - | -$35.02 M(-58.0%) | -$62.45 M(+29.4%) |
| Mar 2021 | - | -$83.32 M(-207.8%) | -$48.24 M(-223.8%) |
| Dec 2020 | $38.97 M(-154.5%) | $77.28 M(-461.3%) | $38.97 M(-210.7%) |
| Sept 2020 | - | -$21.39 M(+2.8%) | -$35.21 M(-11.3%) |
| June 2020 | - | -$20.81 M(-634.4%) | -$39.72 M(-1.8%) |
| Mar 2020 | - | $3.90 M(+25.7%) | -$40.43 M(-43.5%) |
| Dec 2019 | -$71.58 M(-23.0%) | $3.10 M(-112.0%) | -$71.58 M(-30.6%) |
| Sept 2019 | - | -$25.90 M(+20.3%) | -$103.06 M(+3.3%) |
| June 2019 | - | -$21.53 M(-21.0%) | -$99.77 M(+1.4%) |
| Mar 2019 | - | -$27.25 M(-4.0%) | -$98.38 M(+5.9%) |
| Dec 2018 | -$92.92 M(+15.0%) | -$28.39 M(+25.6%) | -$92.92 M(+12.1%) |
| Sept 2018 | - | -$22.60 M(+12.3%) | -$82.86 M(+3.8%) |
| June 2018 | - | -$20.13 M(-7.6%) | -$79.85 M(-3.1%) |
| Mar 2018 | - | -$21.80 M(+18.9%) | -$82.44 M(+2.0%) |
| Dec 2017 | -$80.83 M(+20.2%) | -$18.33 M(-6.5%) | -$80.83 M(+1.5%) |
| Sept 2017 | - | -$19.59 M(-13.8%) | -$79.64 M(+5.2%) |
| June 2017 | - | -$22.72 M(+12.6%) | -$75.72 M(+8.6%) |
| Mar 2017 | - | -$20.18 M(+17.7%) | -$69.72 M(+3.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2016 | -$67.27 M(+168.1%) | -$17.14 M(+9.3%) | -$67.27 M(+35.1%) |
| Sept 2016 | - | -$15.67 M(-6.3%) | -$49.78 M(+62.2%) |
| June 2016 | - | -$16.73 M(-5.6%) | -$30.70 M(+26.6%) |
| Mar 2016 | - | -$17.73 M(-5208.1%) | -$24.25 M(-3.4%) |
| Dec 2015 | -$25.09 M(-57.5%) | $347.00 K(-89.8%) | -$25.09 M(-41.3%) |
| Sept 2015 | - | $3.41 M(-133.2%) | -$42.78 M(-20.2%) |
| June 2015 | - | -$10.28 M(-44.6%) | -$53.64 M(-11.6%) |
| Mar 2015 | - | -$18.57 M(+7.1%) | -$60.70 M(+2.7%) |
| Dec 2014 | -$59.11 M(-16.9%) | -$17.34 M(+132.8%) | -$59.11 M(+3.9%) |
| Sept 2014 | - | -$7.45 M(-57.1%) | -$56.90 M(-16.2%) |
| June 2014 | - | -$17.34 M(+2.2%) | -$67.91 M(-1.5%) |
| Mar 2014 | - | -$16.98 M(+12.2%) | -$68.96 M(-3.1%) |
| Dec 2013 | -$71.17 M(-18.7%) | -$15.13 M(-18.0%) | -$71.17 M(-6.4%) |
| Sept 2013 | - | -$18.46 M(+0.4%) | -$76.03 M(-3.2%) |
| June 2013 | - | -$18.39 M(-4.1%) | -$78.55 M(-2.8%) |
| Mar 2013 | - | -$19.18 M(-4.0%) | -$80.85 M(-7.6%) |
| Dec 2012 | -$87.54 M(-15.3%) | -$19.99 M(-4.7%) | -$87.54 M(-0.6%) |
| Sept 2012 | - | -$20.97 M(+1.3%) | -$88.08 M(-7.4%) |
| June 2012 | - | -$20.69 M(-20.0%) | -$95.10 M(-0.6%) |
| Mar 2012 | - | -$25.88 M(+26.1%) | -$95.68 M(-7.4%) |
| Dec 2011 | -$103.30 M(-23.5%) | -$20.53 M(-26.7%) | -$103.30 M(-12.4%) |
| Sept 2011 | - | -$28.00 M(+31.6%) | -$117.90 M(-8.7%) |
| June 2011 | - | -$21.28 M(-36.5%) | -$129.16 M(-7.3%) |
| Mar 2011 | - | -$33.50 M(-4.6%) | -$139.35 M(+3.2%) |
| Dec 2010 | -$135.07 M(+60.9%) | -$35.13 M(-10.5%) | -$135.07 M(+7.1%) |
| Sept 2010 | - | -$39.25 M(+24.7%) | -$126.17 M(+13.5%) |
| June 2010 | - | -$31.47 M(+7.7%) | -$111.15 M(+39.5%) |
| Mar 2010 | - | -$29.22 M(+11.4%) | -$79.68 M(+57.9%) |
| Dec 2009 | -$83.97 M(+100.8%) | -$26.23 M(+8.2%) | -$50.46 M(+108.2%) |
| Sept 2009 | - | -$24.24 M | -$24.24 M |
| Dec 2008 | -$41.82 M(+91.7%) | - | - |
| Dec 2007 | -$21.81 M | - | - |
FAQ
- What is Pacific Biosciences of California annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Pacific Biosciences of California?
- What is Pacific Biosciences of California annual EBITDA year-on-year change?
- What is Pacific Biosciences of California quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Pacific Biosciences of California?
- What is Pacific Biosciences of California quarterly EBITDA year-on-year change?
- What is Pacific Biosciences of California TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Pacific Biosciences of California?
- What is Pacific Biosciences of California TTM EBITDA year-on-year change?
What is Pacific Biosciences of California annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of PACB is -$297.66 M
What is the all time high annual EBITDA for Pacific Biosciences of California?
Pacific Biosciences of California all-time high annual earnings before interest, taxes, depreciation & amortization is $38.97 M
What is Pacific Biosciences of California annual EBITDA year-on-year change?
Over the past year, PACB annual earnings before interest, taxes, depreciation & amortization has changed by -$15.42 M (-5.46%)
What is Pacific Biosciences of California quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of PACB is -$53.54 M
What is the all time high quarterly EBITDA for Pacific Biosciences of California?
Pacific Biosciences of California all-time high quarterly earnings before interest, taxes, depreciation & amortization is $77.28 M
What is Pacific Biosciences of California quarterly EBITDA year-on-year change?
Over the past year, PACB quarterly earnings before interest, taxes, depreciation & amortization has changed by +$14.99 M (+21.88%)
What is Pacific Biosciences of California TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of PACB is -$339.08 M
What is the all time high TTM EBITDA for Pacific Biosciences of California?
Pacific Biosciences of California all-time high TTM earnings before interest, taxes, depreciation & amortization is $38.97 M
What is Pacific Biosciences of California TTM EBITDA year-on-year change?
Over the past year, PACB TTM earnings before interest, taxes, depreciation & amortization has changed by -$53.07 M (-18.56%)